Status:
COMPLETED
EXPLORATORY STUDY Addendum to INVAC1-CT-101 (NCT02301754)
Lead Sponsor:
Invectys
Conditions:
Solid Tumor, Adult
Eligibility:
All Genders
18+ years
Phase:
PHASE1
Brief Summary
This study will be an exploratory study of long term immunogenicity of INVAC-1 in patients who participated in the INVAC1-CT-101 phase I study (between 2014 and 2018).
Detailed Description
The primary goal of the study is to analyze anti-telomerase specific memory responses in blood of long term survival patients and to correlate these immune responses to their subsequent treatment sinc...
Eligibility Criteria
Inclusion
- Patients who participated in the phase I study and are still alive at the present time
- Ability to provide written informed consent and to understand and comply with the requirements of the study.
Exclusion
- Anemia (Hgb \< 7g/dL) according to L-1121-1 annexe 2 of Code de Santé Publique
- Systolic blood pressure below 90 mm Hg
Key Trial Info
Start Date :
October 16 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 19 2020
Estimated Enrollment :
6 Patients enrolled
Trial Details
Trial ID
NCT04515043
Start Date
October 16 2020
End Date
December 19 2020
Last Update
June 1 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Saint Louis Hospital
Paris, France, 75010